Oxford, UK, 14 June 2022 – Nucleome Therapeutics (“Nucleome”, “the Company”), a biotechnology company decoding the dark matter of the human genome to uncover novel ways to treat disease, today announces the appointment of Dina Anderson as Vice President of Operations with immediate effect.

Dina is a seasoned pharmaceutical R&D leader with 25 years of experience in academia, start-up biotechs and large pharma. She has a proven track record of delivery across the R&D lifecycle including operational leadership roles in research, development, project management and post-marketing medical initiatives. Most recently, Dina served as Vice President of Preclinical Development at DJS Antibodies, having previously worked at both Allergan and Ipsen.

“Dina brings a wealth of operational experience in biotech and pharma which will be key in expanding our operational capabilities across critical business functions to support the next phase of Nucleome’s growth, making her a key addition to the team,” commented Dr Danuta Jeziorska, Chief Executive Officer and Founder of Nucleome. “As the Company continues to decipher the dark genome, initiates new drug discovery programmes and ultimately moves towards the clinic, bringing the complex activities and different elements of the organisation together is vital for our continued success.”

Dina Anderson, Vice President of Operations, said: “I am delighted to have the opportunity to join Nucleome at such an exciting stage of growth. I believe that the Company’s breakthrough technology, which has the potential to unlock the value within the dark genome, can bring about a paradigm shift in drug discovery. I am excited to work with Nucleome’s impressive team to utilise and exploit this technology to transform patient care.”

– End –

Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat disease. The dark genome holds more than 90% of disease-linked genetic variants whose value remains untapped, representing a significant opportunity for drug discovery and development. We have the unique ability to link these variants to gene function and map disease pathways. Our cell type-specific platform creates high resolution 3D genome structure maps and enables variant functional validation at scale in primary cell types. This enables us to discover and develop novel, better and safer drugs. The initial focus of the company is on lymphocytes and related autoimmune disease. Our ambition is to build a robust pipeline of drug assets, with corresponding biomarkers. Nucleome Therapeutics was founded by leading experts in gene regulation from the University of Oxford and backed by investment from Oxford Science Enterprises. For more information, please visit www.nucleome.com.